Al-Ola A Abdallah, Director of Plasma Cell Disorders Care at The University of Kansas Health System and Chair of USMIRC, shared on X:
“PFS in relapsed myeloma:
- Cilta-cel: 59.4% at 30 months
- Teclistamab plus daratumumab: 83.4% at 36 months
- Ide-cel: median 13.8 months
Different trials, populations and follow-up. This descriptive overlay cannot establish treatment superiority.”
Other posts about Relapsed Myeloma on OncoDaily.